Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Lenalidomide, a potent immunomodulatory drug (IMiD), is primarily used in the treatment of hematologic malignancies. Its chemical identity is defined by the molecular formula C13H13N3O4 and the CAS registry number 191732-72-6. Structurally, it serves as an analog of thalidomide but possesses enhanced potency with a more favorable safety profile regarding teratogenicity, although strict pregnancy prevention programs remain mandatory due to residual risks.
The primary clinical application of lenalidomide involves multiple myeloma, a cancer of plasma cells. It is approved for use in newly diagnosed patients in combination with dexamethasone, particularly for those ineligible for autologous stem cell transplantation. Additionally, it is a standard therapy for relapsed or refractory multiple myeloma following one prior line of treatment. Beyond myeloma, lenalidomide is indicated for the treatment of transfusion-dependent anemia associated with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS) characterized by a deletion 5q cytogenetic abnormality. It also plays a crucial role in managing mantle cell lymphoma after at least one prior therapy.
Mechanistically, lenalidomide functions through a multi-faceted approach. It binds to cereblon, a component of an E3 ubiquitin ligase complex, leading to the degradation of specific transcription factors such as Ikaros and Aiolos. This action modulates the immune system by enhancing T-cell and natural killer cell activity while inhibiting angiogenesis and directly inducing apoptosis in malignant cells. The drug is typically administered orally in capsule form, often on a cyclic schedule depending on the specific disease protocol. Common adverse effects include fatigue, neutropenia, thrombocytopenia, and an increased risk of venous thromboembolism, necessitating careful patient monitoring and prophylactic anticoagulation in many cases. As a cornerstone agent in modern hematology, lenalidomide has significantly improved progression-free survival and overall outcomes for patients with various blood cancers, representing a major advancement over previous therapeutic options.